FUSN Fusion Pharmaceuticals


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
Fusion Pharmaceuticals Inc. (the “Company”) held its annual meeting of shareholders on June 4, 2021 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted in the following manner with respect to the following proposals:

1.The election of Directors, each to serve until the 2022 annual meeting of shareholders. The final voting results were as follows:

Donald Bergstrom, M.D., Ph.D.19,607,77109,418
Pablo Cagnoni, M.D.19,604,489012,700
Johan Christenson, Ph.D.19,607,77109,418
Barbara Duncan17,243,74702,373,442
Steve Gannon19,607,71109,478
Philina Lee, Ph.D.19,607,67209,517
Chau Khuong19,607,77109,418
Heather Preston, M.D.19,568,069049,120
John Valliant, Ph.D.19,607,77109,418

2.The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm the current fiscal year ending December 31, 2021 was approved as follows: